CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-16 | Tessari Eben Chief Operating Officer | Shares withheld for taxes | −681 | $10.13 | $7K | 109,063 |
| 2022-03-16 | Tessari Eben Chief Operating Officer | Option exercise · Restricted Share Unit | −1,964 | 5,892 | ||
| 2022-01-15 | Megna Michael R Chief Accounting Officer | Grant or award | +653 | $9.63 | $6K | 3,424 |
| 2022-01-15 | Moat Ross Chief Commercial Officer | Grant or award | +1,546 | $9.63 | $15K | 5,891 |
| 2022-01-15 | Tessari Eben Chief Operating Officer | Grant or award | +970 | $9.63 | $9K | 107,780 |
| 2021-10-04 | Megna Michael R Chief Accounting Officer | Grant or award · Restricted Share Units | +700 | 700 | ||
| 2021-09-02 | Tessari Eben Chief Business Officer | Grant or award · Share Option | +47,138 | 47,138 | ||
| 2021-09-02 | Tessari Eben Chief Business Officer | Grant or award · Restricted Share Units | +7,856 | 7,856 | ||
| 2021-09-02 | Megna Michael R Chief Accounting Officer | Grant or award · Share Option | +6,195 | 6,195 | ||
| 2021-09-02 | Megna Michael R Chief Accounting Officer | Grant or award · Restricted Share Units | +3,098 | 3,098 | ||
| 2021-09-02 | Pano Arian Chief Clinical Dev. Officer | Grant or award · Share Option | +23,325 | 23,325 | ||
| 2021-09-02 | Pano Arian Chief Clinical Dev. Officer | Grant or award · Restricted Share Units | +3,888 | 3,888 | ||
| 2021-09-02 | Ragosa Mark Chief Financial Officer | Grant or award · Share Option | +44,661 | 44,661 | ||
| 2021-09-02 | Ragosa Mark Chief Financial Officer | Grant or award · Restricted Share Units | +7,444 | 7,444 | ||
| 2021-09-02 | Moat Ross ARCALYST General Manager | Grant or award · Share Option | +7,954 | 7,954 | ||
| 2021-09-02 | Moat Ross ARCALYST General Manager | Grant or award · Restricted Share Units | +3,977 | 3,977 | ||
| 2021-09-02 | Paolini John F. Chief Medical Officer | Grant or award · Share Option | +41,400 | 41,400 | ||
| 2021-09-02 | Paolini John F. Chief Medical Officer | Grant or award · Restricted Share Units | +6,900 | 6,900 | ||
| 2021-09-02 | Patel Sanj K Chairman & CEO | Grant or award · Share Option | +157,658 | 157,658 | ||
| 2021-09-02 | Patel Sanj K Chairman & CEO | Grant or award · Restricted Share Units | +26,276 | 26,276 |
Page 70 of 74 · 1,467 trades